Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting

Preclinical data with SC262, a HIP-modified CD22-directed allogeneic CAR T cell, further support completed IND submission Validation of novel and fully-human GPRC5D-specific CARs for the development...

Related Keywords

United States ,San Diego ,California ,South San Francisco ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Nicole Keith ,Sana Biotechnology Inc ,American Society Of Hematology ,Nasdaq ,American Society ,Annual Meeting ,Terry Fry ,Senior Vice President ,Cells That Evade Innate ,Adaptive Immune Rejection ,Multiple Myeloma ,Sana Biotechnology ,Quarterly Report ,Markets ,